Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
Androgens in Health and Disease.pdf - E Library
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
446 Index<br />
Pituitary adenoma, male hypogonadism, 428<br />
Pituitary adenylate cyclase-activat<strong>in</strong>g polypeptide<br />
(PACAP), fetal testosterone<br />
biosynthesis regulation, 8<br />
Platelet, effects of testosterone, 208<br />
Polycystic ovarian syndrome (PCOS),<br />
cardiovascular disease, 129, 130<br />
coronary artery disease, 193, 194, 198, 199<br />
diagnostic criteria, 125<br />
gynecological cancer association, 129<br />
<strong>in</strong>fertility, 128, 129<br />
<strong>in</strong>sul<strong>in</strong> resistance, 129<br />
natural history, 128<br />
treatment,<br />
anti<strong>and</strong>rogens, 134, 135<br />
f<strong>in</strong>asteride, 135<br />
hirsutism, 131, 132, 135<br />
<strong>in</strong>sul<strong>in</strong> sensitizers,<br />
metform<strong>in</strong>, 134<br />
thiazolid<strong>in</strong>ediones, 134<br />
lifestyle modification, 132, 133<br />
ornith<strong>in</strong>e decarboxylase <strong>in</strong>hibitors, 133<br />
ovarian suppressive therapies, 133<br />
overview, 131, 132<br />
spironolactone, 134, 135<br />
surgery, 136<br />
Polycythemia, <strong>and</strong>rogen therapy association, 238,<br />
239, 355, 356<br />
Precocious puberty, def<strong>in</strong>ition, 335<br />
Pregnenolone, testosterone conversion pathways, 4–6<br />
Progest<strong>in</strong>s, male contraception, 410–412<br />
Prolact<strong>in</strong>, testosterone synthesis regulation studies, 8<br />
Prolact<strong>in</strong>oma, hypogonadism, 66, 67<br />
Prostate,<br />
ag<strong>in</strong>g effects, 352<br />
<strong>and</strong>rogen receptor expression, 157, 158<br />
development, 157<br />
knockout mouse studies, effects on differentiation<br />
<strong>and</strong> function,<br />
aromatase, 97<br />
estrogen receptor, 97<br />
Prostate cancer,<br />
<strong>and</strong>rogen ablation therapy,<br />
adjunctive therapy, 177<br />
apoptosis <strong>in</strong>duction,<br />
mitochondrial pathway, 174<br />
prostate cancer cell l<strong>in</strong>e studies, 175, 176<br />
rat ventral prostate studies, 174, 175<br />
receptor-mediated apoptosis, 172, 173<br />
metastatic prostate cancer, 176–178<br />
side effects, 177<br />
<strong>and</strong>rogen dependence, 164<br />
<strong>and</strong>rogen receptor,<br />
activation,<br />
lig<strong>and</strong>-<strong>in</strong>dependent activation, 169, 170<br />
nongenomic effects, 170<br />
mutations,<br />
<strong>and</strong>rogen-<strong>in</strong>dependent cancer, 164<br />
CAG repeats, 168, 169<br />
detection, 165<br />
ga<strong>in</strong>-of-function mutations, 165, 167, 168<br />
latent prostate cancer mutations, 167<br />
loss-of-function mutations, 168<br />
overview, 38, 116, 117, 166, 167<br />
<strong>and</strong>rogen replacement therapy risks, 178, 328,<br />
356, 357<br />
epidemiology, 157, 161<br />
steroid 5α-reductase <strong>in</strong>hibitor therapy, 81, 82<br />
testosterone levels <strong>and</strong> cancer risks,<br />
fetal development, 161, 162<br />
nested case control studies, 163<br />
racial differences, 163<br />
Prostate serum antigen (PSA), <strong>and</strong>rogen replacement<br />
therapy monitor<strong>in</strong>g, 328, 329<br />
PSA, see Prostate serum antigen<br />
Puberty,<br />
<strong>and</strong>rogen replacement therapy,<br />
constitutional delay of growth <strong>and</strong> puberty,<br />
341, 342<br />
permanent hypogonadism, 342–344<br />
body composition changes, 336<br />
bone maturation <strong>and</strong> sex steroids, 336–341<br />
def<strong>in</strong>ition, 335<br />
dehydroepi<strong>and</strong>rosterone levels, 338<br />
estrogen levels, 338<br />
flutamide effects, 340<br />
gonadotrop<strong>in</strong> secretion, 336, 337<br />
growth hormone-sex steroid <strong>in</strong>teractions,<br />
338, 339<br />
growth spurt, 336<br />
ox<strong>and</strong>rolone role <strong>in</strong> growth, 339, 340<br />
precocious puberty, 335<br />
secondary sexual characteristics, 336<br />
sexual function <strong>and</strong> <strong>and</strong>rogens,<br />
females, 269, 270<br />
males, 264–266<br />
tamoxifen effects, 340<br />
testosterone levels, 337<br />
R<br />
Radiation therapy, hypogonadism <strong>in</strong>duction, 62, 63<br />
Red blood cell, see Erythropoiesis<br />
Reifenste<strong>in</strong> syndrome, features, 59<br />
Renal failure, see Uremia<br />
S<br />
SARMs, see Selective <strong>and</strong>rogen receptor modulators<br />
SBMA, see Sp<strong>in</strong>al bulbar muscular atrophy